Stephan Michels

6.6k total citations · 1 hit paper
121 papers, 5.1k citations indexed

About

Stephan Michels is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Stephan Michels has authored 121 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Ophthalmology, 68 papers in Radiology, Nuclear Medicine and Imaging and 13 papers in Molecular Biology. Recurrent topics in Stephan Michels's work include Retinal Diseases and Treatments (92 papers), Retinal Imaging and Analysis (48 papers) and Retinal and Optic Conditions (42 papers). Stephan Michels is often cited by papers focused on Retinal Diseases and Treatments (92 papers), Retinal Imaging and Analysis (48 papers) and Retinal and Optic Conditions (42 papers). Stephan Michels collaborates with scholars based in Switzerland, Austria and Germany. Stephan Michels's co-authors include Ursula Schmidt‐Erfurth, W. Geitzenauer, Philip J. Rosenfeld, Matthias Becker, Carmen A. Puliafito, Franz Prager, H. Laqua, Geeta A. Lalwani, Gottfried O.H. Naumann and Anne E. Fung and has published in prestigious journals such as SHILAP Revista de lepidopterología, Scientific Reports and Ophthalmology.

In The Last Decade

Stephan Michels

115 papers receiving 4.9k citations

Hit Papers

An Optical Coherence Tomo... 2007 2026 2013 2019 2007 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular Degeneration
    2007 802 citations Anne E. Fung, Geeta A. Lalwani et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Stephan Michels 4.6k 3.1k 663 538 233 121 5.1k
Christina J. Flaxel 5.7k 1.2× 4.3k 1.4× 564 0.9× 701 1.3× 159 0.7× 145 6.3k
Thomas S. Hwang 4.7k 1.0× 4.2k 1.4× 396 0.6× 1.4k 2.6× 108 0.5× 117 5.5k
James M. Klancnik 4.5k 1.0× 2.9k 0.9× 558 0.8× 388 0.7× 136 0.6× 50 4.8k
Daniela Ferrara 3.4k 0.8× 2.5k 0.8× 611 0.9× 276 0.5× 52 0.2× 84 3.7k
David Sarraf 6.3k 1.4× 4.3k 1.4× 815 1.2× 343 0.6× 252 1.1× 259 7.0k
Dennis A. Orlock 2.8k 0.6× 2.1k 0.7× 297 0.4× 314 0.6× 201 0.9× 31 3.4k
Talisa E. de Carlo 3.3k 0.7× 2.8k 0.9× 185 0.3× 634 1.2× 103 0.4× 55 3.6k
Rosa Dolz‐Marco 2.8k 0.6× 1.8k 0.6× 547 0.8× 162 0.3× 71 0.3× 155 3.1k
Michael J. Cooney 3.3k 0.7× 2.3k 0.7× 442 0.7× 308 0.6× 145 0.6× 41 4.0k
Salvatore Grisanti 2.6k 0.6× 1.9k 0.6× 884 1.3× 138 0.3× 98 0.4× 192 3.3k

Countries citing papers authored by Stephan Michels

Since Specialization
Citations

This map shows the geographic impact of Stephan Michels's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephan Michels with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephan Michels more than expected).

Fields of papers citing papers by Stephan Michels

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephan Michels. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephan Michels. The network helps show where Stephan Michels may publish in the future.

Co-authorship network of co-authors of Stephan Michels

This figure shows the co-authorship network connecting the top 25 collaborators of Stephan Michels. A scholar is included among the top collaborators of Stephan Michels based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephan Michels. Stephan Michels is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Michels, Stephan, et al.. (2024). Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series. BMC Ophthalmology. 24(1). 520–520. 8 indexed citations
2.
Wons, Juliana, et al.. (2019). Optical Coherence Tomography Angiography (OCT-A) in a Patient with Occult Retinal Dysfunction. SHILAP Revista de lepidopterología. 2019. 1–7. 2 indexed citations
3.
Wons, Juliana, Magdalena A. Wirth, Nicole Graf, Matthias Becker, & Stephan Michels. (2017). Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept. Journal of Ophthalmology. 2017. 1–8. 9 indexed citations
4.
Winnik, Stephan, Christine Lohmann, Tobias von Lukowicz, et al.. (2013). Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis – implications for cardiovascular safety. International Journal of Cardiology. 168(3). 2453–2461. 81 indexed citations
5.
Kloeckener‐Gruissem, Barbara, Moreno Menghini, Daniel Barthelmes, et al.. (2011). A Swiss Patient Cohort Reveals Genetic Predisposition Of Known And New Genetic Loci To AMD And To Intravitreal Ranibizumab (lucentis®) Treatment Outcome. Investigative Ophthalmology & Visual Science. 52(14). 5249–5249. 2 indexed citations
6.
Prager, Franz, et al.. (2008). Intravitreal Bevacizumab (Avastin®) Monotherapy versus Photodynamic Therapy Plus Intravitreal Triamcinolone for Neovascular Age-Related Macular Degeneration:12 Months Results of a Prospective, Randomized, Controlled Clinical Trial. Investigative Ophthalmology & Visual Science. 49(13). 1168–1168. 2 indexed citations
7.
Sacu, Stefan, et al.. (2007). Comparison of Reduced Fluence versus Standard Fluence Verteporfin Therapy in Combination With Intravitreal Triamcinolone Acetonide: A Prospective, Randomized, Controlled Clinical Trial. Investigative Ophthalmology & Visual Science. 48(13). 1831–1831. 1 indexed citations
8.
Fung, Anne E., Geeta A. Lalwani, Stephan Michels, et al.. (2007). Characteristics of Patients Losing Vision at Year 1 of the PrONTO Study. Investigative Ophthalmology & Visual Science. 48(13). 4579–4579. 1 indexed citations
9.
Lalwani, Geeta A., Anne E. Fung, Stephan Michels, et al.. (2007). An OCT-Guided Variable-Dosing Regimen With Ranibizumab (Lucentis) in Neovascular AMD: Two Year Results of the PrONTO Study. Investigative Ophthalmology & Visual Science. 48(13). 1834–1834. 2 indexed citations
10.
Kiss, Christopher, Julia Wagner, Christian Simader, Stephan Michels, & Ursula Schmidt‐Erfurth. (2007). Effect of Photodynamic Therapy (PDT) and Ranibizumab on Vascular Anatomy and Retinal Function in Neovascular Age-Related Macular Degeneration. Investigative Ophthalmology & Visual Science. 48(13). 4544–4544. 5 indexed citations
11.
Fung, Anne E., et al.. (2006). Visual Acuity Outcomes Following a Variable–Dosing Regimen for Ranibizumab (LucentisTM) in Neovascular AMD: The PrONTO Study. Investigative Ophthalmology & Visual Science. 47(13). 2958–2958. 11 indexed citations
12.
Michels, Stephan, et al.. (2006). VEGF 165 Serum Levels Following Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration. Investigative Ophthalmology & Visual Science. 47(13). 2173–2173. 1 indexed citations
13.
Funk, Marion, Stephan Michels, Julia Wagner, et al.. (2006). Vascular Effects of Combined Ranibizumab (Lucentis®) and Verteporfin (Visudyne®) Therapy in Patients With Neovascular Age–Related Macular Degeneration. Investigative Ophthalmology & Visual Science. 47(13). 353–353. 2 indexed citations
14.
Kiss, Christopher, Stephan Michels, W. Geitzenauer, Franz Prager, & Ursula Schmidt‐Erfurth. (2006). Anterior Chamber Inflammatory Activity in Patients With Neovascular Age–Related Macular Degeneration Treated With Intravitreal Bevacizumab (Avastin®). Investigative Ophthalmology & Visual Science. 47(13). 2171–2171. 1 indexed citations
15.
Wagner, Julia, Christian Simader, Christopher Kiss, et al.. (2006). Changes in Functional Macular Mapping in Patients With Neovascular Age–Related Macular Degeneration Receiving Combination of Verteporfin (Visudyne®) and Ranibizumab (LucentisTM) Therapy. Investigative Ophthalmology & Visual Science. 47(13). 363–363. 2 indexed citations
16.
Schmidt‐Erfurth, Ursula, Rainer A. Leitgeb, Stephan Michels, et al.. (2005). Three–Dimensional Ultrahigh Resolution Optical Coherence Tomography (3D UHR OCT): A Video Presentation. Investigative Ophthalmology & Visual Science. 46(13). 1115–1115. 1 indexed citations
17.
Hermann, Boris, Stephan Michels, Rainer A. Leitgeb, et al.. (2005). Thickness Mapping of Photoreceptors of the Foveal Region in Normals Using Three–Dimensional Optical Coherence Tomography. Investigative Ophthalmology & Visual Science. 46(13). 3971–3971. 3 indexed citations
18.
Rosenfeld, Philip J., Carmen A. Puliafito, Stephan Michels, et al.. (2005). Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration (SANA) Study: Visual Acuity Outcomes. Investigative Ophthalmology & Visual Science. 46(13). 2310–2310.
19.
Kiss, Christopher, Rainer A. Leitgeb, Stephan Michels, et al.. (2005). Retinal Vasculature Imaging Using Three Dimensional Ultra–High Resolution Optical Coherence Tomography. Investigative Ophthalmology & Visual Science. 46(13). 3467–3467. 1 indexed citations
20.
Simader, Christian, Julia Wagner, Christopher Kiss, et al.. (2005). Characteristic Findings in Stratus OCT in Patients With Predominantly Occult Choroidal Neovascularization (CNV) in Age–Related Macular Degeneration Treated With Verteporfin Therapy and Intravitreal Triamcinolone. Investigative Ophthalmology & Visual Science. 46(13). 315–315. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christina J. Flaxel Breakdown of academic impact, for papers by Thomas S. Hwang Breakdown of academic impact, for papers by James M. Klancnik Breakdown of academic impact, for papers by Daniela Ferrara Breakdown of academic impact, for papers by David Sarraf Breakdown of academic impact, for papers by Dennis A. Orlock Breakdown of academic impact, for papers by Talisa E. de Carlo Breakdown of academic impact, for papers by Rosa Dolz‐Marco Breakdown of academic impact, for papers by Michael J. Cooney Breakdown of academic impact, for papers by Salvatore Grisanti
Rankless by CCL
2026